BUNAZOSIN HYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H27N5O3.ClH
Molecular Weight	409.91
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CCCC(=O)N1CCCN(CC1)C2=NC(N)=C3C=C(OC)C(OC)=CC3=N2

InChI

InChIKey=NBGBEUITCPENLJ-UHFFFAOYSA-N

InChI=1S/C19H27N5O3.ClH/c1-4-6-17(25)23-7-5-8-24(10-9-23)19-21-14-12-16(27-3)15(26-2)11-13(14)18(20)22-19;/h11-12H,4-10H2,1-3H3,(H2,20,21,22);1H

HIDE SMILES / InChI

Description
Sources: http://www.e-search.ne.jp/~jpr/PDF/EISAI03.PDF
Curator's Comment: description was created based on several sources, including: DOI: 10.1111/j.1527-3466.1988.tb00517.x | https://medikamio.com/de-de/medikamente/andante-3mg/pil | doi: 10.1016/B978-008055232-3.61351-0 | http://adisinsight.springer.com/drugs/800004823

Bunazosin (E-643) is a quinazoline derivative with a1-adrenoceptor blocking activity. It has been clinically used both as a systemic antihypertensive as well as an ocular hypotensive drug. The major adverse effect associated with the use of bunazosin is orthostatic hypotension or its consequences (e.g. dizziness). Others adverse effects include headache, sweating, nausea, dry mouth, abdominal pain, diarrhea, and constipation. The effects of Bunazosin may be enhanced by diuretics and other antihypertensive agents and decreased by Rifampicin.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Adrenergic receptor alpha-1 169 Target ID: CHEMBL1907610 Sources: http://www.e-search.ne.jp/~jpr/PDF/EISAI03.PDF	Blocker 537

Conditions

Condition	Modality	Highest Phase	Product
Hypertension 567 Sources: http://www.e-search.ne.jp/~jpr/PDF/EISAI03.PDF	Primary	Approved 8429	Detantol@R Approved Use Detantol is indicated to treat hypertension.
Glaucoma 57 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15867947 http://adisinsight.springer.com/drugs/800004823	Primary	Phase III 656	Unknown Approved Use Unknown
Chronic obstructive pulmonary disease 174 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6102862	Primary	Basic research	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
The renin-angiotensin and adrenergic nervous system in cardiac hypertrophy in fructose-fed rats.	2002 Jan	11824863
Amelioration by topical bunazosin hydrochloride of the impairment in ocular blood flow caused by nitric oxide synthase inhibition in rabbits.	2003 Feb	12648305
[Effects of ocular hypotensive agents on the circadian rhythm in intraocular pressure in rabbits as measured by telemetry].	2003 Sep	14531310
Additive effect of bunazosin on intraocular pressure when topically added to treatment with latanoprost in patients with glaucoma.	2003 Sep-Oct	12967873
Alterations of alpha-adrenergic modulations of coronary microvascular tone in dogs with heart failure.	2005 Jun	15948090
An alpha1-receptor blocker reduces plasma leptin levels in hypertensive patients with obesity and hyperleptinemia.	2006 Oct	17283868
[Case of pigmentary glaucoma treated with medical therapy, laser treatment, and trabeculotomy].	2007 Feb	17338326
New perspectives of infections in cardiovascular disease.	2009 May	20436849

Patents

Sample Use Guides

In Vivo Use Guide

3 to 9 mg once daily. The administration should be started at a dose of 3 mg once daily and the maximum daily dose of 9 mg should not be exceeded.

Route of Administration: Oral

In Vitro Use Guide

[3H]bunazosin binds specifically to rat brain preparation with a Bmax value of 84.6 fmol/mg protein and a Kd value of 0.59 nM.

Name

Type

Language

BUNAZOSIN HYDROCHLORIDE

Common Name

English

BUNAZOSIN HCL

Common Name

English

BUNAZOSIN HYDROCHLORIDE [JAN]

Common Name

English

DETANTOL

Brand Name

English

BUNAZOSIN HYDROCHLORIDE [MI]

Common Name

English

E-643

Code

English

Bunazosin hydrochloride [WHO-DD]

Common Name

English

1-BUTANONE, 1-(4-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)HEXAHYDRO-1H-1,4-DIAZEPIN-1-YL)-, HYDROCHLORIDE (1:1)

Systematic Name

English

BUNAZOSIN HYDROCHLORIDE [MART.]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29713